Difference between revisions of "Cabozantinib (Cometriq)"
Jump to navigation
Jump to search
m |
(FDA approval) |
||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Tyrosine kinase inhibitor; inhibits RET, MET/c-Met, VEGFR-1, VEGFR-2, VEGFR-3, KIT, TRKB, FLT-3, AXL, and TIE-2.<ref name="insert">[http://www.cometriq.com/downloads/Cometriq_Full_Prescribing_Information.pdf Cabozantinib (Cometriq) package insert]</ref><ref>[[Media:Cabozantinib.pdf | Cabozantinib (Cometriq) package insert (locally hosted backup)]]</ref><ref>[http://www.cometriq.com/ Cometriq manufacturer's website]</ref> | + | Class/mechanism: Tyrosine kinase inhibitor; inhibits RET, MET/c-Met, VEGFR-1, VEGFR-2, VEGFR-3, KIT, TRKB, FLT-3, AXL, and TIE-2.<ref name="insert">[http://www.cometriq.com/downloads/Cometriq_Full_Prescribing_Information.pdf Cabozantinib (Cometriq) package insert]</ref><ref>[[Media:Cabozantinib.pdf | Cabozantinib (Cometriq) package insert (locally hosted backup)]]</ref><ref>[http://www.cometriq.com/ Cometriq manufacturer's website]</ref><ref name="insert_Cabometyx">[https://www.cabometyx.com/downloads/CABOMETYXUSPI.pdf Cabozantinib (Cabometyx) package insert]</ref><ref>[[Media:Cabozantinib cabometyx.pdf | Cabozantinib (Cabometyx) package insert (locally hosted backup)]]</ref><ref>[https://www.cabometyx.com/ Cabometyx manufacturer's website]</ref> |
<br>Route: PO | <br>Route: PO | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref><ref name="insert_Cabometyx"></ref> |
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| Line 13: | Line 13: | ||
==Patient drug information== | ==Patient drug information== | ||
*[http://www.cometriq.com/downloads/Cometriq_Full_Prescribing_Information.pdf#page=20 Cabozantinib (Cometriq) package insert pages 20-24]<ref name=insert></ref> (the numbering for the PDF is off, so in some PDF viewers, the patient information is on pages 27-31) | *[http://www.cometriq.com/downloads/Cometriq_Full_Prescribing_Information.pdf#page=20 Cabozantinib (Cometriq) package insert pages 20-24]<ref name=insert></ref> (the numbering for the PDF is off, so in some PDF viewers, the patient information is on pages 27-31) | ||
| + | *[https://www.cabometyx.com/downloads/CABOMETYXUSPI.pdf Cabozantinib (Cabometyx) package insert]<ref name="insert_Cabometyx"></ref> | ||
*[http://www.chemocare.com/chemotherapy/drug-info/cabozantinib.aspx Cabozantinib (Cometriq) patient drug information (Chemocare)]<ref>[http://www.chemocare.com/chemotherapy/drug-info/cabozantinib.aspx Cabozantinib (Cometriq) patient drug information (Chemocare)]</ref> | *[http://www.chemocare.com/chemotherapy/drug-info/cabozantinib.aspx Cabozantinib (Cometriq) patient drug information (Chemocare)]<ref>[http://www.chemocare.com/chemotherapy/drug-info/cabozantinib.aspx Cabozantinib (Cometriq) patient drug information (Chemocare)]</ref> | ||
*[http://www.uptodate.com/contents/cabozantinib-patient-drug-information Cabozantinib (Cometriq) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/cabozantinib-patient-drug-information Cabozantinib (Cometriq) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/cabozantinib-patient-drug-information Cabozantinib (Cometriq) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/cabozantinib-patient-drug-information Cabozantinib (Cometriq) patient drug information (UpToDate)]</ref> | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | *11/29/2012: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm330213.htm FDA approved] for treatment of "progressive metastatic [[Thyroid_cancer#Medullary_thyroid_cancer | medullary thyroid cancer (MTC)]]" | + | *11/29/2012: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm330213.htm FDA approved] (as Cometriq) for treatment of "progressive metastatic [[Thyroid_cancer#Medullary_thyroid_cancer | medullary thyroid cancer (MTC)]]" |
| − | *4/25/2016: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm497483.htm FDA approved] for the treatment of [[Renal_cancer|advanced renal cell carcinoma]] in patients who have received prior [[:Category:VEGF_inhibitors|anti-angiogenic therapy]]. | + | *4/25/2016: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm497483.htm FDA approved] (as Cabometyx) "for the treatment of [[Renal_cancer|advanced renal cell carcinoma]] in patients who have received prior [[:Category:VEGF_inhibitors|anti-angiogenic therapy]]." |
==Also known as== | ==Also known as== | ||
| − | XL184 or XL-184. | + | XL184 or XL-184. '''Cometriq is the brand name for cabozantinib's medullary thyroid cancer indication. Cabometyx is the brand name for cabozantinib's renal cell carcinoma indication.''' |
==References== | ==References== | ||
Revision as of 07:34, 26 April 2016
General information
Class/mechanism: Tyrosine kinase inhibitor; inhibits RET, MET/c-Met, VEGFR-1, VEGFR-2, VEGFR-3, KIT, TRKB, FLT-3, AXL, and TIE-2.[1][2][3][4][5][6]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1][4]
Diseases for which it is used
Patient drug information
- Cabozantinib (Cometriq) package insert pages 20-24[1] (the numbering for the PDF is off, so in some PDF viewers, the patient information is on pages 27-31)
- Cabozantinib (Cabometyx) package insert[4]
- Cabozantinib (Cometriq) patient drug information (Chemocare)[7]
- Cabozantinib (Cometriq) patient drug information (UpToDate)[8]
History of changes in FDA indication
- 11/29/2012: FDA approved (as Cometriq) for treatment of "progressive metastatic medullary thyroid cancer (MTC)"
- 4/25/2016: FDA approved (as Cabometyx) "for the treatment of advanced renal cell carcinoma in patients who have received prior anti-angiogenic therapy."
Also known as
XL184 or XL-184. Cometriq is the brand name for cabozantinib's medullary thyroid cancer indication. Cabometyx is the brand name for cabozantinib's renal cell carcinoma indication.
References
- ↑ 1.0 1.1 1.2 Cabozantinib (Cometriq) package insert
- ↑ Cabozantinib (Cometriq) package insert (locally hosted backup)
- ↑ Cometriq manufacturer's website
- ↑ 4.0 4.1 4.2 Cabozantinib (Cabometyx) package insert
- ↑ Cabozantinib (Cabometyx) package insert (locally hosted backup)
- ↑ Cabometyx manufacturer's website
- ↑ Cabozantinib (Cometriq) patient drug information (Chemocare)
- ↑ Cabozantinib (Cometriq) patient drug information (UpToDate)